1 |
Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12):1537-41.
DOI
|
2 |
Kremers HM, McEvoy MT, Dann FJ, Gabriel SE. Heart disease in psoriasis. J Am Acad Dermatol. 2007;57(2):347-54.
DOI
|
3 |
Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829-35.
DOI
|
4 |
Heymann WR. Psoriasis: the heart of the matter. J Am Acad Dermatol. 2008;58(3):477-8.
DOI
|
5 |
Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53(4):573.
|
6 |
Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol. 2008;159(2):322-30.
DOI
|
7 |
Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340(2):115-26.
DOI
|
8 |
Fernandez-Sanchez A, Madrigal-Santillan E, Bautista M, et al. Inflammation, oxidative stress, and obesity. Int J Mol Sci. 2011; 12(5):3117-32.
DOI
|
9 |
McArdle MA, Finucane OM, Connaughton RM, et al. Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies. Front Endocrinol (Lausanne). 2013;4:52.
|
10 |
Berk M, Williams LJ, Jacka FN, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 2013;11:200.
DOI
|
11 |
Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med. 2017;376(15):1492.
|
12 |
Liu C, Huang Y. Chinese Herbal Medicine on Cardiovascular Diseases and the Mechanisms of Action. Front Pharmacol. 2016;7:469.
|
13 |
Griffiths CE, Katsambas A, Dijkmans BA, Finlay AY, Ho VC, Johnston A, et al. Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol. 2006;155 Suppl 2:1-16.
|
14 |
Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321-8.
DOI
|
15 |
Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32(6):982-6.
DOI
|
16 |
Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401-7.
DOI
|
17 |
Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25(6):529-34.
DOI
|
18 |
Medzhitov R, Origin and physiological roles of inflammation. Nature. 2008; 454(7203):428-35.
DOI
|
19 |
Rainer H. Straub, Carsten Schradin. Chronic inflammatory systemic diseases: An evolutionary trade-off betweenacutely beneficial but chronically harmful programs, Evol Med Public Health. 2016;2016(1):37-51.
|
20 |
Netea MG, Balkwill F, Chonchol M, et al. A guiding map for inflammation. Nat Immunol. 2017;18(8):826-31.
DOI
|
21 |
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509.
DOI
|
22 |
Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-85.
DOI
|
23 |
Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205-12.
DOI
|
24 |
Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69:4-9.
DOI
|
25 |
Rousset L, Halioua B. Stress and psoriasis. Int J Dermatol. 2018;57(10):1165-172.
DOI
|
26 |
Zachariae R, Zachariae H, Blomqvist K, et al. Self-reportedstress reactivity and psoriasis-related stress of nordic psoriasissufferers. J Eur Acad Dermatol Venereol. 2004;18(1):27-36.
DOI
|
27 |
Song H, Fang F, Tomasson G, et al. Association of Stress-Related Disorders With Subsequent Autoimmune Disease. JAMA. 2018;319(23):2388-400.
DOI
|
28 |
Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J. 2015;36(8):482-9c.
DOI
|
29 |
Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and metaanalysis of observational studies. Nutr Diabetes. 2012;2:e54.
DOI
|
30 |
Dogra S, Mahajan R. Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatol Online J. 2016;7(6):471-80.
DOI
|
31 |
Reich K, The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012;26:3-11.
DOI
|
32 |
Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001; 103(13):1813-8.
DOI
|
33 |
Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol. 2004; 29(8):439-93.
DOI
|
34 |
Mora S, Lee IM, Buring JE, Ridker PM. Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA. 2006;295(12):1412-9.
DOI
|
35 |
Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol. 2008;159(2):322-30.
DOI
|
36 |
Correia B, Torres T. Obesity: a key component of psoriasis. Acta Biomed. 2015;86(2):121-9.
|
37 |
Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol. 2007;157(4):649-55.
DOI
|
38 |
Ryan C, Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin. 2015;33(1):41-55.
DOI
|
39 |
Naldi L, Peli L, Parazzini F. Association of Early-Stage Psoriasis With Smoking and Male Alcohol Consumption: evidence From an Italian Case-Control Study. Arch Dermatol. 1999;135(12):1479-84.
|
40 |
Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130(7):1785-96.
DOI
|
41 |
Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082.
DOI
|
42 |
Meng S, Lin Z, Wang Y, Wang Z, Li P, Zheng Y. Psoriasis therapy by Chinese medicine and modern agents. Chin Med. 2018;13:16.
DOI
|
43 |
Guan F, Lam W, Hu R, et al. Majority of Chinese Medicine Herb Category "Qing Re Yao" Have Multiple Mechanisms of Antiinflammatory Activity. Sci Rep. 2018;8(1):7416.
DOI
|
44 |
Cheng H-M, Wu Y-C, Wang Q, et al. Clinical efficacy and IL-17 targeting mechanism of Indigo naturalis as a topical agent in moderate psoriasis. BMC Complement Altern Med. 2017;17(1):439.
DOI
|
45 |
Vandevoorde V, Haegeman G, Fiers W. TNF-mediated IL6 gene expression and cytotoxicity are co-inducible in TNFresistant L929 cells. FEBS Lett. 1992;302(3):235-8.
DOI
|
46 |
De Sa DC, Festa Neto C. Inflammasomes and dermatology. An Bras Dermatol. 2016;91(5):566-78.
DOI
|
47 |
Tozser J, Benko S. Natural Compounds as Regulators of NLRP3 Inflammasome-Mediated IL- Production. Mediators Inflamm. 2016;2016:5460302.
|
48 |
Lin X, Huang T, Oxidative stress in psoriasis and potential therapeutic use of antioxidants. Free Radic Res. 2016;50(6):585-95.
DOI
|
49 |
Wang D, Gu J, Zhu W, et al. PDTCM: a systems pharmacology platform of traditional Chinese medicine for psoriasis. Ann Med. 2017;49(8):652-60.
DOI
|
50 |
Hirayama A, Oowada S, Ito H, et al. Clinical significance of redox effects of Kampo formulae, a traditional Japanese herbal medicine: comprehensive estimation of multiple antioxidative activities. J Clin Biochem Nutr. 2018;62(1):39-48.
|
51 |
Wu M, Deng Y, Li S, et al. The Immunoregulatory Effects of Traditional Chinese Medicine on Psoriasis via its Action on Interleukin: Advances and Considerations. Am J Chin Med. 2018;46(4):739-50.
DOI
|
52 |
Lin YK, Chang YC, Hui RC, et al. A Chinese Herb, Indigo Naturalis, Extracted in Oil (Lindioil) Used Topically to Treat Psoriatic Nails: A Randomized Clinical Trial. JAMA Dermatol. 2015;151(6):672-4.
DOI
|
53 |
Yan Y, Liu W, Andres P, et al. Exploratory clinical trial to evaluate the efficacy of a topical traditional chinese herbal medicine in psoriasis vulgaris. Evid Based Complement Alternat Med. 2015;2015:719641.
|
54 |
Lin YK, See LC, Huang YH, Comparison of indirubin concentrations in indigo naturalis ointment for psoriasis treatment: a randomized, double-blind, dosage-controlled trial. Br J Dermatol. 2018;178(1):124-31.
DOI
|
55 |
Sun W, Gao Y, Yu X, et al. 'Psoriasis 1' reduces psoriasis-like skin inflammation by inhibiting the VDR-mediated nuclear NF- and STAT signaling pathways. Mol Med Rep. 2018;18(3):2733-43.
|
56 |
Geng X, Shi H, Ye F, et al. Matrine inhibits itching by lowering the activity of calcium channel. Sci Rep. 2018;8(1):11328.
DOI
|
57 |
Lu C, Liu H, Jin X. Herbal Components of a Novel Formula PSORI-CM02 Interdependently Suppress Allograft Rejection and Induce CD8+CD122+PD-1+ Regulatory T Cells. Front Pharmacol. 2018;9:88.
DOI
|
58 |
Liu Q, Yin W, Han L, et al. Diarylheptanoid from rhizomes of Curcuma kwangsiensis (DCK) inhibited imiquimod-induced dendritic cells activation and Th1/Th17 differentiation. Int Immunopharmacol. 2018;56:339-48.
DOI
|
59 |
Parker S, Zhang CS, Yu JJ, et al. Oral Chinese herbal medicine versus placebo for psoriasis vulgaris: A systematic review. J Dermatolog Treat. 2017;28(1):21-31.
DOI
|
60 |
Zhang CS, Yang L, Zhang AL, et al. Is Oral Chinese Herbal Medicine Beneficial for Psoriasis Vulgaris? A Meta-Analysis of Comparisons with Acitretin. J Altern Complement Med. 2016;22(3):174-88.
DOI
|